These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30994802)

  • 21. Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis.
    Mistro S; Gomes B; Rosa L; Miranda L; Camargo M; Badaró R
    Trop Med Int Health; 2017 Dec; 22(12):1569-1578. PubMed ID: 29078022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug combinations for visceral leishmaniasis.
    Olliaro PL
    Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of visceral leishmaniasis.
    Sundar S; Rai M
    Expert Opin Pharmacother; 2005 Dec; 6(16):2821-9. PubMed ID: 16318433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budgetary impact of diagnostic tests for visceral leishmaniasis in Brazil.
    Assis TSM; Azeredo-da-Silva ALF; Oliveira D; Cota G; Werneck GL; Rabello A
    Cad Saude Publica; 2017 Dec; 33(12):e00142416. PubMed ID: 29267689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for death from visceral leishmaniasis in patients treated with liposomal amphotericin B in an endemic state in Brazil.
    Dias Tourinho B; Figueiredo Amâncio F; Lencine Ferraz M; Carneiro M
    Trans R Soc Trop Med Hyg; 2017 Apr; 111(4):163-171. PubMed ID: 28673017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visceral leishmaniasis in an infant gorilla (Gorilla gorilla gorilla): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B.
    Tinoco HP; da Costa MELT; Pessanha AT; Coelho CM; de Carvalho TF; Mol JPDS; Viana AG; Bueno LL; Fujiwara RT; Santos RL
    J Med Primatol; 2018 Dec; 47(6):416-418. PubMed ID: 29956831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.
    Meheus F; Boelaert M; Baltussen R; Sundar S
    Trop Med Int Health; 2006 Nov; 11(11):1715-24. PubMed ID: 17054752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 31. How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis.
    Boelaert M; Le Ray D; Van Der Stuyft P
    Trop Med Int Health; 2002 Nov; 7(11):955-9. PubMed ID: 12390602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of amphotericin B lipid complex for kala-azar.
    Basnyat B
    Ann Intern Med; 1998 Feb; 128(4):326. PubMed ID: 9471948
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deadly parasitic disease grips southern Sudan.
    Gulland A
    BMJ; 2002 Nov; 325(7373):1133. PubMed ID: 12433757
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis.
    Boelaert M; Lynen L; Desjeux P; Van der Stuyft P
    Bull World Health Organ; 1999; 77(8):667-74. PubMed ID: 10516788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic considerations about visceral leishmaniasis. Two case report.
    Pasticci MB; Papili R; Menichetti F; Ballanti S; Ottaviani L; Tabilio A; Stagni G
    Infez Med; 2002 Sep; 10(3):176-8. PubMed ID: 12704269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune haemolytic anaemia due to visceral leishmaniasis in a young child.
    Boel M
    Eur J Pediatr; 2003 Jun; 162(6):444; author reply 445. PubMed ID: 12712333
    [No Abstract]   [Full Text] [Related]  

  • 39. Study of implementation and direct cost estimates for diagnostic tests for human visceral leishmaniasis in an urban area in Brazil.
    Assis TS; Guimarães PN; Oliveira E; Peruhype-Magalhães V; Gomes LI; Rabello A
    Cad Saude Publica; 2015 Oct; 31(10):2127-36. PubMed ID: 26735380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.
    Thornton SJ; Wasan KM; Piecuch A; Lynd LL; Wasan EK
    Drug Dev Ind Pharm; 2010 Nov; 36(11):1312-9. PubMed ID: 20545513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.